Skip to content

Randomized, double-blind, parallel controlled, multicenter clinical trial on the efficacy and safety of Qingjin Pingchuan Tang in the treatment of children with bronchial asthma during the onset stage (heat induced asthma syndrome) in combination with Maxing Shigan Tang and Suting Wan group

Study on diagnosis and treatment of bronchial asthma in children with Chinese and Western medicine

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300074829
Enrollment
Unknown
Registered
2023-08-17
Start date
2023-09-01
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

childhood bronchial asthma

Interventions

experimental group:to "qingjinpingchuan"soup
control group:to "maxingganshi and suting"soup

Sponsors

Children's Hospital, Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
5 Years to 12 Years

Inclusion criteria

Inclusion criteria: (1) In line with the Western medicine diagnostic criteria for children with bronchial asthma and the traditional Chinese medicine syndrome differentiation criteria for heat asthma; (2) 5 years old = age =12 years old, gender is not limited; (3) No traditional Chinese and western medicines were used to treat the disease within 48 hours before enrollment; (4) Can cooperate with pulmonary ventilation function examination; (5) The informed consent process complies with the regulations, and the legal guardian signs the informed consent.

Exclusion criteria

Exclusion criteria: (1) Children with bronchial asthma in the critical stage, or patients with fever =48h during screening, and complicated diseases such as laryngitis, pneumonia, and septicemia. (2) Serious primary diseases of heart, lung, liver, kidney, metabolism, hematopoietic, immune, nervous, mental and other systems. (3) People who are allergic to the experimental drug or have related drug contraindications. (4) Participants who have participated in other trials within the last 3 months. (5) Other conditions deemed unsuitable for participation in this study after evaluation by the researcher.

Design outcomes

Primary

MeasureTime frame
pulmonary function test;16S rDNA gene sequence of fecal intestinal flora;

Secondary

MeasureTime frame
blood routine examination;CRP;

Countries

China

Contacts

Public ContactWu Fang

Children's Hospital, Zhejiang University School of Medicine

yunianchengyifu@163.com+86 138 1912 5711

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026